TLPH Stock Overview
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Talphera, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.03 |
52 Week High | US$1.61 |
52 Week Low | US$0.42 |
Beta | 0.54 |
1 Month Change | -24.82% |
3 Month Change | 40.14% |
1 Year Change | 47.14% |
3 Year Change | -96.97% |
5 Year Change | -98.49% |
Change since IPO | -98.87% |
Recent News & Updates
Recent updates
AcelRx: The Catalogue Of Catalysts - Including A Big One That Will Do Investors Well
Aug 18AcelRx Pharmaceuticals: Finally, Plan B
Jun 06AcelRx Pharmaceuticals: Making Sense Of The Q4 Numbers
Mar 16AcelRx Pharmaceuticals: The Fog Is Getting Thicker
Jan 14AcelRx: Battered And Bruised But Ready For Recovery In 2022
Jan 05AcelRx Pharmaceuticals: Is Wayne Gretzky Right Or The Puck?
Oct 02AcelRx Pharmaceuticals: How The Licensing Agreements Could Become A Shot In The Arm
Jul 27FDA agrees with AcelRx to update promotional materials for Dsuvia
Jun 17Shareholders May Find It Hard To Justify Increasing AcelRx Pharmaceuticals, Inc.'s (NASDAQ:ACRX) CEO Compensation For Now
Jun 11AcelRx Pharmaceuticals: A Bullish View In 3 Song Titles
May 31When Will AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Turn A Profit?
Feb 03Shareholder Returns
TLPH | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -8.0% | 2.2% | 0.2% |
1Y | 47.1% | 25.5% | 28.1% |
Return vs Industry: TLPH exceeded the US Pharmaceuticals industry which returned 25.8% over the past year.
Return vs Market: TLPH exceeded the US Market which returned 28.8% over the past year.
Price Volatility
TLPH volatility | |
---|---|
TLPH Average Weekly Movement | 18.0% |
Pharmaceuticals Industry Average Movement | 9.7% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TLPH's share price has been volatile over the past 3 months.
Volatility Over Time: TLPH's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2005 | 15 | Vince Angotti | https://talphera.com |
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.
Talphera, Inc. Fundamentals Summary
TLPH fundamental statistics | |
---|---|
Market cap | US$18.67m |
Earnings (TTM) | -US$10.29m |
Revenue (TTM) | US$651.00k |
26.8x
P/S Ratio-1.7x
P/E RatioIs TLPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
TLPH income statement (TTM) | |
---|---|
Revenue | US$651.00k |
Cost of Revenue | US$498.00k |
Gross Profit | US$153.00k |
Other Expenses | US$10.44m |
Earnings | -US$10.29m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.61 |
Gross Margin | 23.50% |
Net Profit Margin | -1,580.18% |
Debt/Equity Ratio | 0% |
How did TLPH perform over the long term?
See historical performance and comparison